Avantor Investor Conference Presentation Deck
...and Avantor is uniquely positioned to capture
biopharma market share
RESEARCH & DEVELOPMENT
MSD Growth Rate
-50% of
Biopharma
Revenue¹
- Unparalleled access
- Extensive portfolio
- Onsite service associates
- Collaboration that seeds
bioproduction
Navantor™
CLINICAL & BIOREPOSITORY
HSD-DD Growth Rate
-10% of
1. Based on management estimate assuming all M&A as of 1/1/21
Biopharma
Revenue¹
- Scale-up and clinical trial services
- Custom kitting, packaging
- Equipment sourcing, deployment
and management
- Storage and archiving for
regulated environments
2
BIOPRODUCTION
3
DD Growth Rate
~40% of
Biopharma
Revenue¹
4
- Collaboration to support process
optimization
- Broad range of GMP materials
- Highly characterized
chromatography resins, solutions
- Robust pipeline of new products
40th Annual J.P. Morgan Healthcare Conference
12View entire presentation